Komori
Qol Holdings (3034) · RiskFirst stated

Advertising and fair competition regulations specific to the pharmaceutical industry

First written in FY2021. . Latest entry: FY2021.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Advertising and fair competition regulations specific to the pharmaceutical industryA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2021First statedAnnual report

    「In providing various services, our Group pays particular attention to industry-specific regulations, including restrictions on advertising under the Pharmaceuticals and Medical Devices Act and the Fair Competition Code Concerning Restrictions on the Provision of Premiums in the Manufacturing of Prescription Drugs, established by the Japan Fair Trade Commission, as well as other regulations specific to the pharmaceutical industry.」

    The company disclosed industry-specific regulations as a risk, separate from general legal requirements, including advertising restrictions under the Pharmaceuticals and Medical Devices Act and fair competition codes in the pharmaceutical industry.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Qol Holdings's next results are scheduled for 2026-11-05. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.